Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1998 Jun;13(6):667-76.
doi: 10.2165/00019053-199813060-00003.

The economic burden of migraine to society

Affiliations
Review

The economic burden of migraine to society

M D Ferrari. Pharmacoeconomics. 1998 Jun.

Abstract

The financial burden of migraine on society comprises direct costs, associated with medical care, and indirect costs, caused by absence from work and reduced productivity. Recent studies have revealed that direct costs are generally relatively low in Europe, but are much higher in North America, probably because of increased use of emergency room and specialist consultations for the treatment of migraine. Most individuals who experience migraine headaches take medication (over-the-counter, prescription-only or a combination of both) for their condition; in Europe and North America, most patients who experience migraines have consulted a physician at some time because of their condition. In general, the estimated indirect costs of migraine are substantial and are much higher than estimates of direct costs. On average, work losses related to reduced productivity are higher than those related to work absence. These data demonstrate the importance of the societal impact of migraine and illustrate the need for improved strategies to target migraine treatment.

PubMed Disclaimer

References

    1. JAMA. 1989 Nov 17;262(19):2708-13 - PubMed
    1. Pharmacoeconomics. 1995 Feb;7(2):170-9 - PubMed
    1. Headache. 1993 Jan;33(1):29-35 - PubMed
    1. Psychiatry Res. 1991 Apr;37(1):11-23 - PubMed
    1. Pharmacoeconomics. 1992 Jul;2(1):67-76 - PubMed